2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12953
    R-268712 879487-87-3 ≥98.0%
    R-268712 is an orally active and selective ALK-5 inhibitor, with an IC50 of 2.5 nM. R-268712 inhibits the phosphorylation of Smad3 in a dose-dependent manner with an IC50 of 10.4 nM. R-268712 suppresses glomerulonephritis as well as glomerulosclerosis by inhibiting TGF-β signaling, which can be used in studies of renal fibrosis and cancer.
    R-268712
  • HY-B0735A
    Fenoldopam mesylate 67227-57-0 99.94%
    Fenoldopam mesylate (SKF-82526) is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis.
    Fenoldopam mesylate
  • HY-P99050
    Sutimlimab 2049079-64-1 98.81%
    Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome.
    Sutimlimab
  • HY-A0096
    Iloprost 78919-13-8 ≥99.0%
    Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research.
    Iloprost
  • HY-B2106
    Polidocanol,Hydroxyl Value 40-60 mgKOH/g 9002-92-0 ≥98.0%
    Polidocanol is a sclerosing agent used successfully to treat extremity and esophageal varices and telangiectasias.
    Polidocanol,Hydroxyl Value 40-60 mgKOH/g
  • HY-P4094
    CTP 1052692-86-0 99.66%
    CTP (cardiac targeting peptide) can transduce cardiomyocytes in vitro. CTP leads to efficient and specific transduction of heart tissue in mice model. CTP can be reversibly linked (e.g. via enolases, thiol groups) to cargo (e.g. miRNAs) for delivery specifically to cardiomyocytes over all other organs.
    CTP
  • HY-103334
    MAFP 188404-10-6 ≥98.0%
    MAFP (Methyl Arachidonyl Fluorophosphonate) is an selective, active-site directed and irreversible inhibitor of cPLA2 and iPLA2. MAFP is also a potent irreversible inhibitor of anandamide amidase.
    MAFP
  • HY-113298
    Citraconic acid 498-23-7 ≥98.0%
    Citraconic acid (Methylmaleic acid) is an orally active inhibitor targeting the NLRP3 inflammasome and Keap1-Nrf2 pathway. Citraconic acid reduces reactive oxygen species (ROS) generation by inhibiting succinate dehydrogenase (SDH) activity. Citraconic acid also modifies the conformation of Keap1 protein, relieves its inhibition of Nrf2, promotes antioxidant gene expression, and inhibits NLRP3 activation and the release of pro-inflammatory factors such as IL-1β and IL-18. Citraconic acid has anti-inflammatory and antioxidant activities, can reduce oxidative stress and cell pyroptosis, improve tissue damage, and can be used for the research of inflammation-related diseases such as acute renal ischemia-reperfusion injury. Citraconic acid is an isomer of Itaconic acid (HY-Y052).
    Citraconic acid
  • HY-152086A
    DRP1i27 dihydrochloride 98.63%
    DRP1i27 dihydrochloride is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 dihydrochloride binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 dihydrochloride targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury.
    DRP1i27 dihydrochloride
  • HY-30004
    1-Aminocyclopropane-1-carboxylic acid 22059-21-8 ≥98.0%
    1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity..
    1-Aminocyclopropane-1-carboxylic acid
  • HY-137383
    Sulfo-SANPAH 102568-43-4 99.72%
    Sulfo-SANPAH is a primary amine-nitrobenzene azide cross-linker.
    Sulfo-SANPAH
  • HY-131180
    BMS-986235 2253947-47-4 99.74%
    BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC50s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failure.
    BMS-986235
  • HY-12343
    ML277 1401242-74-7 98.46%
    ML277 (CID-53347902) is a potent and selective activator of K(v)7.1 (KCNQ1) potassium channel activator (EC50=270 nM), rescues function of pathophysiologically important mutant channel complexes in human induced pluripotent stem cell-derived cardiomyocytes.
    ML277
  • HY-17003
    Saquinavir mesylate 149845-06-7 99.84%
    Saquinavir (Ro 31-8959) mesylate is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir mesylate also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir mesylate
  • HY-B0553
    Methazolamide 554-57-4 99.41%
    Methazolamide (L584601) is a BBB-penetrable and orally active carbonic anhydrase inhibitor, with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage.
    Methazolamide
  • HY-18206A
    Lisinopril dihydrate 83915-83-7 99.96%
    Lisinopri dihydrate (MK-521 dihydrate) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
    Lisinopril dihydrate
  • HY-119695A
    Simvastatin acid ammonium 139893-43-9 99.70%
    Simvastatin acid (Tenivastatin) ammonium is a potent HMG-CoA reductase (HMGCR) inhibitor. Simvastatin acid ammonium reduces Indoxyl sulfate-mediated reactive oxygen species (ROS) production in human cardiomyocytes. Simvastatin acid ammonium can also modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene.
    Simvastatin acid ammonium
  • HY-B0076
    Bisoprolol hemifumarate 104344-23-2 99.84%
    Bisoprolol hemifumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol hemifumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
    Bisoprolol hemifumarate
  • HY-N8241
    N-trans-Caffeoyltyramine 103188-48-3 99.71%
    N-TRANS-CaffeoyLtyramine is an effective inflammatory response regulator, which has antioxidant activity and anticoagulation effects.
    N-trans-Caffeoyltyramine
  • HY-Y1103
    Iron(II) sulfate heptahydrate, 99% 7782-63-0 ≥99.0%
    Iron(II) sulfate heptahydrate, 99% (Ferrous sulfate heptahydrate, 99%) is an orally active iron salt. Iron(II) sulfate heptahydrate, 99% replaces iron found in hemoglobin and myoglobin, allowing for the transportation of oxygen via hemoglobin. Iron(II) sulfate heptahydrate, 99% is mainly used for the prevention of iron-deficiency anemia. Iron(II) sulfate heptahydrate, 99% also has anti-tumor effects on chronic myeloid leukemia and breast cancer.
    Iron(II) sulfate heptahydrate, 99%
Cat. No. Product Name / Synonyms Application Reactivity